Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Decrease in mean visual analogue score (VAS) for pain and analgesics used at 1 and 3 months after percutaneous vertebroplasty (PV) in patients with vertebral compression fractures (VCF) with absent bone marrow edema (no BME) prior to PV and patients with full BME (full BME) in treated VCF
Follow-up Period after PV
1 Month 3 Months
Mean Decrease VAS Mean Decrease Analgesics Mean Decrease VAS Mean Decrease Analgesics
No BME 5.1 43% 0.4 0%
Full BME 5.8 84% 0.5 13%
Regression coefficient .7 .9 .09 .07
99% Confidence interval −1–2.4 0.1–1.7 −0.7–0.9 −0.4–0.5

	Follow-up Period after PV
	1 Month		3 Months
	Mean Decrease VAS	Mean Decrease Analgesics	Mean Decrease VAS	Mean Decrease Analgesics
No BME	5.1	43%	0.4	0%
Full BME	5.8	84%	0.5	13%
Regression coefficient	.7	.9	.09	.07
99% Confidence interval	−1–2.4	0.1–1.7	−0.7–0.9	−0.4–0.5